This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:

"Individuals with metabolic syndrome have a 2-fold increased risk of cardiovascular disease, but few strategies provide adequate cardiovascular risk reduction for this group. One option to lower this risk is to reduce atherogenic lipids, particularly low-density lipoprotein cholesterol. Statins are a recommended first-line therapy for this purpose, but this approach doesn’t always provide sufficient LDL-C lowering to optimally reduce cardiovascular risk. Now, researchers have shown that alirocumab, a proprotein converstase subtilisin/kexin type 9 inhibitor, or PCSK9 inhibitor, approved for LDL-C reduction, may address this need. Pooled clinical trial data from ten phase 3 clinical trials from the ODYSSEY clinical development program showed alirocumab significantly lowered LDL-C in individuals both with and without metabolic syndrome..."

The rest of the transcript, along with a link to the research itself, is available on the resource itself.

This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:

"Diabetes is a major risk factor for myocardial infarction, stroke, and other cardiovascular diseases. The prime target for reducing cardiovascular risk is low-density lipoprotein, or LDL. LDL cholesterol has been linked to cardiovascular events in patients with type 2 diabetes. While statins have long been the primary treatment for reducing LDL, many patients are unable to reach recommended levels with a statin alone or are unable to take an effective dose. That places them at an especially high risk for cardiovascular disease. Now, a new study reports the efficacy and safety of evolocumab on top of statins in patients with both type 2 diabetes and hyperlipidemia or mixed dyslipidemia. The double-blind, phase 3 trial was conducted in patients from 10 different countries over a treatment period of 12 weeks. More than 980 patients were randomized to one of four subcutaneous treatments: 140 mg of evolocumab every 2 weeks, 420 mg of evolocumab monthly, or placebo at either of those frequencies..."

The rest of the transcript, along with a link to the research itself, is available on the resource itself.

This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:

"Once considered little more than “cell dust”, exosomes are receiving much deserved attention from the research community. Exosomes are tiny sacs whose job includes clearing the cell of certain lipids, proteins, and nucleic acids. But researchers are learning that exosomes are also crucial to signaling and communication between cells. A new review explores various ways exosomes help coordinate the metabolism of lipids in the body. Some of the most promising research describes what happens when exosomes’ ability to synthesize, transport, and degrade lipids is compromised. In some cases, that can lead to disorders such as atherosclerosis, cancer, obesity, and Alzheimer’s disease. Understanding how exosomes orchestrate metabolic activities could clue researchers in on new ways to diagnose and treat related diseases..."

The rest of the transcript, along with a link to the research itself, is available on the resource itself.

This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:

"More than 1 million men are diagnosed with prostate cancer each year Although effective therapies exist, resistance to androgen receptor-targeted therapy is a major challenge in managing the disease Unfortunately, the mechanisms behind therapy resistance are not yet fully understood In a recent study, researchers aimed to identify new targets for treatment against therapy-resistant prostate cancer Using gene expression analysis and 3-dimensional spheroid culture, they examined the interaction of prostate cancer (PCa) cells with cancer-associated fibroblasts (CAFs) The results showed that CAFs in the tumor environment stimulate cholesterol and steroid production in PCa cells This was mediated by pro-inflammatory, pro-migratory, and pro-angiogenic factors secreted by the CAFs, which upregulated genes involved in cholesterol synthesis Blocking cholesterol and steroid production using gene targeting or medication inhibited PCa cell growth Future studies will evaluate the mechanisms underlying the.."

The rest of the transcript, along with a link to the research itself, is available on the resource itself.

This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:

"Cancer and autoimmune disease are two sides of the same coin Autoimmune diseases, such as diabetes, arthritis, and inflammatory bowel disease, are caused by overactivation of the immune response while cancer cells downregulate the immune response in order to promote their own growth One attractive therapeutic target, lymphotoxin β receptor (LTβR) on the cell surface, is central to both processes but its detailed signaling mechanisms have remained unclear, making it difficult to target the pathway Now, researchers have identified a way to alter the strength of LTβR-mediated signaling Using drugs to lower the cholesterol levels in the plasma membrane they showed that the lipid content of the cell membrane affects LTβR-dependent signaling and LTβR internalization Depleting membrane cholesterol caused increased LTβR signaling through the well-known canonical NF-κB signaling pathway suggesting that cholesterol depletion could be used to augment LTβR-based therapies for cancer and choles.."

The rest of the transcript, along with a link to the research itself, is available on the resource itself.

This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:

"A new clinical trial has shown promising results for those trying to shed excess pounds: researchers have zeroed in on a combination of herbal extracts that can significantly increase weight loss under the right circumstances. The news could mean better health for the more than 1 billion people who are overweight or obese worldwide. Traditional pharmaceutical and surgical options for weight management are expensive and often associated with adverse effects. The herbal formulation – composed of extracts from three common culinary spices used in Indian cooking – was developed as a high-quality natural alternative. The combination tackles excess body weight through a multi-layered approach, by both preventing fat cells from maturing and boosting existing fat break down. To determine the safety and efficacy of the extracts, researchers performed a randomized, double-blind, placebo-controlled clinical trial with healthy overweight adults..."

The rest of the transcript, along with a link to the research itself, is available on the resource itself.